Background and Aims: Ambu ® AuraGain™ laryngeal airway (AuraGain) is one of the newer supraglottic airway device introduced in 2014. Cervical spine stabilisation with hard cervical collar makes insertion of supraglottic airways and tracheal intubation difficult. This study was conducted to investigate whether the presence of a cervical collar affects the oropharyngeal sealing pressure (OSP) and fibreoptic view of the glottis (Brimacombe score) in airways secured with the AuraGain. Methods: The study was a randomised crossover trial. Thirty five ASA 1-3 patients undergoing elective surgery under general anaesthesia were recruited for the study. In each patient AuraGain was inserted twice in a crossover manner once with and once without a hard cervical collar in situ , with the sequence of insertion randomised. During each insertion of AuraGain the OSP, fibreoptic view of the glottis, insertion parameters, ventilator data and complications were noted. Results: The mean OSPs in both the groups were similar with no significant difference (29.6 ± 3.7 cmH 2 O without collar and 30.1 ± 3.1 cmH 2 O with collar [ P = 0.310]). The fibreoptic view of glottis was also similar in both groups. The insertion with collar was more difficult than without collar. The number of attempts for successful insertion was same in both the groups. The time taken for appropriate placement of LMA was significantly prolonged in patients with collar. Conclusions: We conclude that the Ambu AuraGain can be used to provide effective ventilation in patients whose cervical spine is immobilised with a hard cervical collar.
Introduction:The potential long-term complication of intraoperative awareness needs to be addressed. These complications range from mild auditory perceptions to being fully awake. Studies with prospective patient interviews that specifically inquire about awareness have noted an incidence of 0.1 to 0.2 percent in the general population and approximately 1 percent in high-risk populations. Aims and Objectives: Comparative evaluation of two dose regimens of propofol to assess the depth of anesthesia during total intravenous anesthesia using Bispectral index monitor. The objectives were to find the average Bispectral index during propofol anaesthesia, compare and determine, in two groups, the amount of additional bolus or reduction in the infusion rates of propofol in two dose regimens and to correlate the Bispectral indices with hemodynamic monitoring and to assess incidence of postoperative awareness in the two groups. Materials and Methods: This study was conducted as a prospective randomized double-blind study in a teaching hospital. After the approval from the Ethics committee of the institution, 50 ASA I-II patients were randomly divided into two groups (GI and GII). The patients were induced with a standard regimen of 2 mg kg -1 of propofol and 0.1 mg kg -1 of vecuronium and intubated using appropriate sized endotracheal tube. Following intubation, propofol was infused according to the group the patients was allotted. GI received propofol infusion maintenance dose of 10 mg kg -1 hour for the first 10 minutes following intubation, 8 mg kg -1 hour for the next 10 minutes and thereafter 6 mg kg -1 hour for the entire length of the surgery. GII received propofol infusion maintenance dose of 8 mg kg -1 hour for the first 10 minutes following intubation, 6 mg kg -1 hour for the next 10 minutes and thereafter 4 mg kg -1 hour for the entire length of the surgery. The Bispectral index, blood pressure and heart rate were monitored during intubation and thereafter every five minutes for the entire length of the surgery. And the propofol dose was adjusted to maintain the Bispectral index between 40 and 60. Results: Additional doses of propofol were required in the GII 8/6/4 mg kg -1 hour regimen when compared to GI 10/8/6 mg kg -1 hour dose regimen. The average Bispectral index was comparable in the two groups. Conclusion: Patients were hemodynamically stable when the Bispectral index was maintained between 40 and 60. Intraoperative awareness was not detected during this study.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.